SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in India, done in May-June, 2020, among adults aged 18 years or older from 21 states, found a SARS-CoV-2 IgG antibody seroprevalence of 0·73% (95% CI 0·34-1·13). We aimed to assess the more recent nationwide seroprevalence in the general population in India. METHODS: We did a second household serosurvey among individuals aged 10 years or older in the same 700 villages or wards within 70 districts in India that were included in the first serosurvey. Individuals aged younger than 10 years and households that did not respond at the time of survey were excluded. Participants were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. 3-5 mL of venous blood was collected from each participant and blood samples were tested using the Abbott SARS-CoV-2 IgG assay. Seroprevalence was estimated after applying the sampling weights and adjusting for clustering and assay characteristics. We randomly selected one adult serum sample from each household to compare the seroprevalence among adults between the two serosurveys. FINDINGS: Between Aug 18 and Sept 20, 2020, we enrolled and collected serum samples from 29 082 individuals from 15 613 households. The weighted and adjusted seroprevalence of SARS-CoV-2 IgG antibodies in individuals aged 10 years or older was 6·6% (95% CI 5·8-7·4). Among 15 084 randomly selected adults (one per household), the weighted and adjusted seroprevalence was 7·1% (6·2-8·2). Seroprevalence was similar across age groups, sexes, and occupations. Seroprevalence was highest in urban slum areas followed by urban non-slum and rural areas. We estimated a cumulative 74·3 million infections in the country by Aug 18, 2020, with 26-32 infections for every reported COVID-19 case. INTERPRETATION: Approximately one in 15 individuals aged 10 years or older in India had SARS-CoV-2 infection by Aug 18, 2020. The adult seroprevalence increased approximately tenfold between May and August, 2020. Lower infection-to-case ratio in August than in May reflects a substantial increase in testing across the country. FUNDING: Indian Council of Medical Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have demonstrated no significant differences in seroprevalence across age groups [54, 57, 61, 62].”
From Impact of COVID-19 on life expectancy at birth in India: a decomposition analysis (2021) · cites this paper as [54]
In the citing paper
“the second and third seroepidemiological surveys in India estimated overall adjusted prevalence of 6.6 [54] and 14.3% [55] infections, respectively, using Abbott IgG assay.”
From Impact of COVID-19 on life expectancy at birth in India: a decomposition analysis (2021) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
Britton, T., Ball, F., & Trapman, P. (2020) · Science · doi:10.1126/science.abc6810 · Cited by 645
Cited by
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Chen, X., Chen, Z., Azman, A. S., Deng, X., Sun, R., Zhao, Z., Zheng, N., Chen, X., Lu, W., Zhuang, T., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00026-7 · Cited by 239
Murhekar, M. V., Bhatnagar, T., Thangaraj, J. W. V., Saravanakumar, V., Kumar, M. S., Selvaraju, S., Rade, K., Kumar, C. P. G., Sabarinathan, R., Turuk, A., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.040 · Cited by 134
Self-citationNkuba, A. N., Makiala, S. M., Guichet, E., Tshiminyi, P. M., Bazitama, Y. M., Yambayamba, M. K., Kazenza, B. M., Kabeya, T. M., Matungulu, E. B., Baketana, L. K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab515 · Cited by 51
“Indeed, several studies have reported a different distribution of seroprevalence according to age, whereas others did not observe age-related differences, eg, in India, Brazil and Zambia, seroprevalence was similar between age groups [16, 17, 19].”
BackgroundImpact of COVID-19 on life expectancy at birth in India: a decomposition analysis
Yadav, S., Yadav, P. K., & Yadav, N. (2021) · BMC Public Health · doi:10.1186/s12889-021-11690-z · Cited by 32
Chang, A. Y., Aaby, P., Avidan, M. S., Benn, C. S., Bertozzi, S. M., Blatt, L., Chumakov, K., Khader, S. A., Kottilil, S., Nekkar, M., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.967920 · Cited by 10
“To be conservative, we assume OPV to be 20 [5-64]% immediate effectiveness 213 against infection and severe illness (not against reducing infectivity among people who 214 are infected) for COVID-19, slightly lower than the assumptions made by others.”
BackgroundResult
Metadata
- Authors
- Murhekar, M. V., Bhatnagar, T., Selvaraju, S., Saravanakumar, V, Thangaraj, J. W. V., Shah, N., Kumar, M. S., Rade, K., Sabarinathan, R., Asthana, S., Balachandar, R., Bangar, S. D., Bansal, A. K., Bhat, J., Chopra, V., Das, D., Deb, A. K., Devi, K. R., Dwivedi, G. R., Khan, S. M. S., Kumar, C. P. G., Kumar, M. S., Laxmaiah, A., Madhukar, M., Mahapatra, A., Mohanty, S. S., Rangaraju, C., Turuk, A., Baradwaj, D. K., Chahal, A. S., Debnath, F., Haq, I., Kalliath, A., Kanungo, S., Kshatri, J. S., Lakshmi, G. G. J. N., Mitra, A., Nirmala, A. R., Prasad, G. V., Qurieshi, M. A., Sahay, S., Sangwan, R. K., Sekar, K., Shukla, V. K., Singh, P. K., Singh, P., Singh, R., Varma, D. S., Viramgami, A., Panda, S., Reddy, D. C. S., Bhargava, B., Andhalkar, R., Chaudhury, A., Deval, H., Dhatrak, S., Gupta, R. R., Ilayaperumal, E., Jagjeevan, B., Jha, R. C., Kiran, K., Krishnan, N. N., Kumar, A., Kumar, V. V., Nagbhushanam, K., Nimmathota, A., Pandey, A. K., Pawar, H. S., Rathore, K. S., Robinson, A., Singh, H. B., Wilson, V. C., Yadav, A., Yadav, R., Karunakaran, T., Pradhan, J., Sivakumar, T., Jose, A., Kalaiyarasi, K., Dasgupta, S., Anusha, R., Anand, T., Babu, G. R., Chauhan, H., Dikid, T., Gangakhedkar, R. R., Kant, S., Kulkarni, S., Muliyil, J. P., Pandey, R. M., Sarkar, S., Shrivastava, A., Singh, S. K., Zodpey, S., Das, A., Das, P., Dutta, S., Kant, R., Narain, K., Narasimhaiah, S., Pati, S., Patil, S., Rajkumar, H., Ramarao, T., Sarkar, K., Singh, S., Toteja, G. S., & Zaman, K.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 9
- Issue
- 3
- Pages
- e257-e266
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W3122600273
- Cited by
- 191
- References
- 8
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. https://app.cochat.ai/papers/10.1016/s2214-109x(20)30544-1
- The paper
- Murhekar, M. V., Bhatnagar, T., Selvaraju, S., Saravanakumar, V, Thangaraj, J. W. V., Shah, N., Kumar, M. S., Rade, K., Sabarinathan, R., Asthana, S., Balachandar, R., Bangar, S. D., Bansal, A. K., Bhat, J., Chopra, V., Das, D., Deb, A. K., Devi, K. R., Dwivedi, G. R., . . . Zaman, K. (2021). SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(20)30544-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.